Rewrite with full clinical detail. Use proper medical terminology. Include dosages, regimen names, biomarker...

CLINICAL REFERENCE DOCUMENTATION: SMALL CELL LUNG CANCER SYSTEMIC THERAPY

Primary Guideline Sources

NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer

• Version 2.2026 ([date removed])
• Category 2A recommendations unless otherwise specified
• Evidence-based consensus from multidisciplinary oncology panel

First-Line Systemic Therapy Regimens

Extensive-Stage SCLC (ES-SCLC)

Preferred Chemoimmunotherapy Regimens:

1. Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3 + Atezolizumab 1200 mg Day 1

   • Cycle length: 21 days × 4 induction cycles
   • Maintenance: Lurbinectedin 3.2 mg/m² + Atezolizumab 1200 mg Day 1 every 21 days
   • Basis: IMpower133 trial (Liu SV et al. J Clin Oncol 2021;39:619-630)
   • Footnote qualifier: Consider lurbinectedin addition in maintenance phase for patients achieving ≥stable disease post-induction, ECOG PS 0-1, without brain metastases history

2. Cisplatin 75 mg/m² Day 1 + Etoposide 100 mg/m² Days 1-3 + Durvalumab 1500 mg Day 1

   • Cycle length: 21 days × 4 induction cycles
   • Optional: Tremelimumab 75 mg Day 1 (single dose)
   • Basis: CASPIAN trial (Goldman JW et al. Lancet Oncol 2021;22:51-65)

3. Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3 + Atezolizumab 1200 mg Day 1

   • Cycle length: 21 days × 4 induction cycles
   • Basis: IMpower133 trial (Horn L et al. N Engl J Med 2018;379:2220-2229)

Alternative Platinum-Based Chemotherapy (without immunotherapy):

• Cisplatin 75 mg/m² Day 1 + Etoposide 100 mg/m² Days 1-3
• Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3
• Irinotecan 60 mg/m² Days 1, 8, 15 + Cisplatin 60 mg/m² Day 1 (21-day cycle)
• Irinotecan 60 mg/m² Days 1, 8, 15 + Carboplatin AUC 5 Day 1 (21-day cycle)

Limited-Stage SCLC (LS-SCLC)

Concurrent Chemoradiotherapy:

1. Cisplatin 75 mg/m² Day 1 + Etoposide 100 mg/m² Days 1-3

   • Concurrent with thoracic radiotherapy (30-35 fractions over 6-7 weeks)
   • Cycles: 4-6 depending on protocol

2. Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3

   • Concurrent with thoracic radiotherapy
   • Alternative for cisplatin-ineligible patients

Adjuvant/Consolidation Therapy:

• Durvalumab 10 mg/kg IV every 2 weeks (Category 1 recommendation)
  • Initiated 1-6 weeks post-chemoradiotherapy completion
  • Duration: up to 12 months
  • Basis: ADRIATIC trial (Cheng Y et al. N Engl J Med 2024;391:1313-1327)

Subsequent Systemic Therapy (Platinum-Sensitive Relapse)

Chemotherapy-Free Interval (CTFI) ≥3 months:

1. Tarlatamab-dlle (DLL3-directed bispecific antibody)

   • Dosing: 10 mg IV weekly (after 2-week lead-in at 5 mg weekly)
   • Basis: KEYNOTE-028 and KEYNOTE-158 studies
   • FDA approval: 2023

2. Lurbinectedin 3.2 mg/m² IV Day 1

   • Cycle length: 21 days
   • Basis: Phase II basket trial (Trigo J et al. Lancet Oncol 2020;21:645-654)
   • FDA approval: 2020

3. Platinum-Based Rechallenge

   • Carboplatin AUC 5 + Etoposide 100 mg/m² (21-day cycle)
   • Cisplatin 60 mg/m² + Etoposide 100 mg/m² (21-day cycle)
   • Basis: Multiple retrospective analyses demonstrating efficacy with CTFI ≥6 months

4. Topotecan

   • IV formulation: 1.5 mg/m² Days 1-5 (21-day cycle)
   • Oral formulation: 2.3 mg/m² daily × 5 days (21-day cycle)
   • Basis: Phase III trials (von Pawel J et al. J Clin Oncol 1999;17:658-667)

Platinum-Resistant Disease (CTFI <3 months):

1. Tarlatamab-dlle (preferred)
2. Lurbinectedin 3.2 mg/m² (21-day cycle)
3. Topotecan (as above dosing)
4. Gemcitabine 1000 mg/m² Days 1, 8, 15 (28-day cycle)
5. Paclitaxel 80-100 mg/m² weekly
6. Temozolomide 150-200 mg/m² Days 1-5 (28-day cycle)
   • Consider MGMT methylation status assessment

Prophylactic Cranial Irradiation (PCI)

Indications:

• Complete response (CR) to initial therapy in both LS-SCLC and ES-SCLC
• Dosing: 25 Gy in 10 fractions (standard) or 30 Gy in 12 fractions

Brain Imaging Surveillance:

• Brain MRI (preferred over CT) more sensitive for metastases detection
• Baseline assessment prior to systemic therapy initiation
• Repeat imaging after every 2 cycles of systemic therapy until:
  • Brain radiotherapy initiation, OR
  • Systemic therapy completion
• If brain metastases progress on systemic therapy: initiate brain RT before completing systemic therapy

Biomarker Considerations

TTF-1 (Thyroid Transcription Factor-1):

• Positive in >90% of SCLC cases
• Diagnostic utility; limited prognostic significance

TP53 Mutations:

• Present in ~70-80% of SCLC
• Not currently actionable for treatment selection

RB1 Alterations:

• Co-mutation with TP53 in majority of cases
• Emerging research; not yet incorporated into treatment algorithms

PD-L1 Expression:

• Prognostic but not predictive of immunotherapy response in SCLC
• Not recommended for treatment selection in current guidelines

Transformed SCLC (from NSCLC)

Clinical Considerations:

• Occurs during EGFR-TKI or other targeted therapy
• Avoid concurrent TKI + immune checkpoint inhibitor (ICI) due to toxicity risk
• Consider referral to specialized centers with transformed SCLC expertise